The CMTA announced November 16, 2015 that its partnership with Genzyme, a Sanofi company, has successfully identified a handful of compound series for treating CMT1A in the next step on the pathway toward drug delivery. Genzyme has been narrowing the number of promising compounds since February, after screeningover 2 million at its Tucson location. The latest data is exciting news for potential drug development candidates for CMT1A. The CMTA’s STAR (Strategy to Accelerate Research) is working!
Your support of CMT research made these outcomes a reality, but there is still more work to be done. Pre-clinical investigation is expensive, and while the CMTA has reduced both the time and the costs, we continue to need resources to fund the development and delivery of treatments to people living with CMT.
Fortunately, one generous CMTA family has pledged to match every dollar designated for CMT1A in the month of November, up to $100,000. Make your donation now to make a difference.
DOUBLE YOUR DONATION TO CMT1A. Click here to DONATE.
Through STAR, we continue our mission to find treatments for CMT1A, 1B, 2A, 2E, X, and Type 4. We believe that together with the CMT community, we will succeed in helping to treat all types of CMT.
You can help! Right now, your gift will help us to realize our vision: A world without CMT. Please be as generous as you possibly can.
Click here to DONATE.
